Loading...
•
Sep 28
Teleflex Q3 2025 Earnings Report
Teleflex reported its financial results for the third quarter ended September 28, 2025, including GAAP and adjusted revenues, diluted EPS, and provided a full year 2025 outlook.
Key Takeaways
Teleflex delivered a strong third quarter, with adjusted operating margin and earnings per share exceeding expectations, and revenue aligning with the midpoint of guidance. The company reported GAAP revenue of $913.0 million, a 19.4% increase year-over-year, and adjusted diluted EPS of $3.67, up from $3.49 in the prior year period. The acquired Vascular Intervention business modestly surpassed its revenue guidance, and integration activities are on track. However, the company recognized significant non-cash impairment charges related to Interventional Urology North America goodwill and the Titan SGS asset group, totaling $403.9 million and $100 million respectively, driven by deteriorating market conditions and lower-than-expected sales growth.
GAAP revenue for Q3 2025 was $913.0 million, an increase of 19.4% compared to the prior year period.
Adjusted diluted EPS from continuing operations for Q3 2025 was $3.67, an increase from $3.49 in the prior year period.
The company recognized a non-cash goodwill impairment charge of $403.9 million related to its Interventional Urology North America reporting unit.
A non-cash impairment charge of $100 million was recognized for the Titan SGS asset group due to lower than expected sales growth and reduced demand.
Teleflex
Teleflex
Teleflex Revenue by Segment
Teleflex Revenue by Geographic Location
Revenue by Segment
Americas Segment Revenue
CapyFin.comEMEA Segment Revenue
CapyFin.comAsia Segment Revenue
CapyFin.comRevenue by Geographic Location
Vascular Access Revenue
CapyFin.comInterventional Revenue
CapyFin.comAnesthesia Revenue
CapyFin.comSurgical Revenue
CapyFin.comInterventional Urology Revenue
CapyFin.comOEM Revenue
CapyFin.comOther Revenue
CapyFin.com Forward Guidance
Teleflex has narrowed its full year 2025 GAAP revenue growth guidance to 9.10% to 9.60% and lowered its adjusted constant currency revenue growth guidance to 6.90% to 7.40%. The company also decreased its GAAP diluted EPS guidance to $(4.42) to $(4.22) and narrowed its adjusted diluted EPS guidance to $14.00 to $14.20.
Positive Outlook
- Narrowed GAAP revenue growth guidance range, indicating more certainty in revenue projections.
- Adjusted diluted EPS guidance narrowed to a higher range ($14.00 to $14.20) compared to previous guidance.
- Estimated positive impact of foreign exchange rate fluctuations of approximately 1.00% for the full year.
- No change to the estimated $204 million in revenues in the second half of 2025 associated with the Vascular Intervention business acquisition.
- Expects to achieve annual pre-tax savings of $24 million to $30 million from the Vascular Intervention Business Integration plan once fully implemented, with savings beginning in 2026.
Challenges Ahead
- Lowered adjusted constant currency revenue growth guidance range due to lower than expected outlook for intra-aortic balloon pump revenue.
- Decreased full year 2025 GAAP diluted earnings per share from continuing operations outlook significantly.
- Lower than expected order rates in the intra-aortic balloon pump portfolio.
- The Italian payback measure adjustments continue to impact reported revenue and require careful reconciliation.
- The integration of the Vascular Intervention business involves restructuring costs estimated to be $36 million to $44 million.
Revenue & Expenses
Visualization of income flow from segment revenue to net income